Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients

Eman M. F. Barakat, Mohamed Kohla, Hossam Dabees, Hend Ibrahim Shousha, Ehab F. Moustafa, Mohamed El-Kassas, Mona Shoukry Aziz, Eman Elkhateeb, Ashraf Omar Abdelaziz, Mohamed Omar Abdelmalek, Aly Azmy, Ahmed Tawheed, Walaa Mosaad Aboganob, Hossam Taha, Rania Lithy, Ahmed Radwan, Dalia Ghoraba, Hamdy Sayed, Anwar Nassief, Mostafa Elhelbawy, Mohamed Mahmoud nabeel, Mohamed A. Medhat, Safaa Ragab Askar, Eman Marwan, Eman Rewisha, Tamer Elbaz, Sayed Hassan Ahmed, Nevien Fouad elfouly, Nermeen Abdeen, Ahmed Hosni Abdelmaksoud, Asmaa A. Abdeltawab, Mostafa Abd Alfattah Shamkh, Ahmed Ramadan, Yasser Arafat Abdelrazek, Mohamed Bassam, Sayed Ahmed Sayed, Rasha Salah Hussein, Ammar Alrajhi, Allam Elsayed Allam, Omnia A. Seyam, Mohamed Said

Open source

DOI: 10.1038/s41598-025-05828-x
Published: 2025-06-27
Container: Scientific Reports
Publisher: Springer Science and Business Media LLC
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41598-025-05828-x,
  title = {Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients},
  author = {Eman M. F. Barakat and Mohamed Kohla and Hossam Dabees and Hend Ibrahim Shousha and Ehab F. Moustafa and Mohamed El-Kassas and Mona Shoukry Aziz and Eman Elkhateeb and Ashraf Omar Abdelaziz and Mohamed Omar Abdelmalek and Aly Azmy and Ahmed Tawheed and Walaa Mosaad Aboganob and Hossam Taha and Rania Lithy and Ahmed Radwan and Dalia Ghoraba and Hamdy Sayed and Anwar Nassief and Mostafa Elhelbawy and Mohamed Mahmoud nabeel and Mohamed A. Medhat and Safaa Ragab Askar and Eman Marwan and Eman Rewisha and Tamer Elbaz and Sayed Hassan Ahmed and Nevien Fouad elfouly and Nermeen Abdeen and Ahmed Hosni Abdelmaksoud and Asmaa A. Abdeltawab and Mostafa Abd Alfattah Shamkh and Ahmed Ramadan and Yasser Arafat Abdelrazek and Mohamed Bassam and Sayed Ahmed Sayed and Rasha Salah Hussein and Ammar Alrajhi and Allam Elsayed Allam and Omnia A. Seyam and Mohamed Said},
  year = {2025},
  journal = {Scientific Reports},
  doi = {10.1038/s41598-025-05828-x},
  url = {https://doi.org/10.1038/s41598-025-05828-x}
}

RIS

TY  - JOUR
TI  - Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients
AU  - Eman M. F. Barakat
AU  - Mohamed Kohla
AU  - Hossam Dabees
AU  - Hend Ibrahim Shousha
AU  - Ehab F. Moustafa
AU  - Mohamed El-Kassas
AU  - Mona Shoukry Aziz
AU  - Eman Elkhateeb
AU  - Ashraf Omar Abdelaziz
AU  - Mohamed Omar Abdelmalek
AU  - Aly Azmy
AU  - Ahmed Tawheed
AU  - Walaa Mosaad Aboganob
AU  - Hossam Taha
AU  - Rania Lithy
AU  - Ahmed Radwan
AU  - Dalia Ghoraba
AU  - Hamdy Sayed
AU  - Anwar Nassief
AU  - Mostafa Elhelbawy
AU  - Mohamed Mahmoud nabeel
AU  - Mohamed A. Medhat
AU  - Safaa Ragab Askar
AU  - Eman Marwan
AU  - Eman Rewisha
AU  - Tamer Elbaz
AU  - Sayed Hassan Ahmed
AU  - Nevien Fouad elfouly
AU  - Nermeen Abdeen
AU  - Ahmed Hosni Abdelmaksoud
AU  - Asmaa A. Abdeltawab
AU  - Mostafa Abd Alfattah Shamkh
AU  - Ahmed Ramadan
AU  - Yasser Arafat Abdelrazek
AU  - Mohamed Bassam
AU  - Sayed Ahmed Sayed
AU  - Rasha Salah Hussein
AU  - Ammar Alrajhi
AU  - Allam Elsayed Allam
AU  - Omnia A. Seyam
AU  - Mohamed Said
PY  - 2025
JO  - Scientific Reports
DO  - 10.1038/s41598-025-05828-x
UR  - https://doi.org/10.1038/s41598-025-05828-x
ER  -

APA

Barakat, E. M. F., Kohla, M., Dabees, H., Shousha, H. I., Moustafa, E. F., El-Kassas, M., Aziz, M. S., Elkhateeb, E., Abdelaziz, A. O., Abdelmalek, M. O., Azmy, A., Tawheed, A., Aboganob, W. M., Taha, H., Lithy, R., Radwan, A., Ghoraba, D., Sayed, H., Nassief, A., Elhelbawy, M., nabeel, M. M., Medhat, M. A., Askar, S. R., Marwan, E., Rewisha, E., Elbaz, T., Ahmed, S. H., elfouly, N. F., Abdeen, N., Abdelmaksoud, A. H., Abdeltawab, A. A., Shamkh, M. A. A., Ramadan, A., Abdelrazek, Y. A., Bassam, M., Sayed, S. A., Hussein, R. S., Alrajhi, A., Allam, A. E., Seyam, O. A., & Said, M. (2025). Tyrosine kinase inhibitors were well-tolerated among patients with different etiologies of advanced HCC with lower survival in non-viral patients. Scientific Reports. https://doi.org/10.1038/s41598-025-05828-x

Source records

crossref · retrieved 2026-09-27T13:21:03.821Z